Mohamad Shebley

1.3k total citations
35 papers, 648 citations indexed

About

Mohamad Shebley is a scholar working on Pharmacology, Reproductive Medicine and Oncology. According to data from OpenAlex, Mohamad Shebley has authored 35 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Reproductive Medicine and 10 papers in Oncology. Recurrent topics in Mohamad Shebley's work include Pharmacogenetics and Drug Metabolism (12 papers), Endometriosis Research and Treatment (11 papers) and Uterine Myomas and Treatments (8 papers). Mohamad Shebley is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Endometriosis Research and Treatment (11 papers) and Uterine Myomas and Treatments (8 papers). Mohamad Shebley collaborates with scholars based in United States, Germany and Switzerland. Mohamad Shebley's co-authors include Ahmed Hamed Salem, Kevin J. Freise, Paul F. Hollenberg, Juki Ng, Nael M. Mostafa, Heidi J. Einolf, Michael Sinz, Odette A. Fahmi, John P. Gibbs and Manoj Chiney and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and British Journal of Clinical Pharmacology.

In The Last Decade

Mohamad Shebley

35 papers receiving 632 citations

Peers

Countries citing papers authored by Mohamad Shebley

Since Specialization

Citations

This map shows the geographic impact of Mohamad Shebley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamad Shebley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamad Shebley more than expected).

Fields of papers citing papers by Mohamad Shebley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamad Shebley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamad Shebley. The network helps show where Mohamad Shebley may publish in the future.

Co-authorship network of co-authors of Mohamad Shebley

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamad Shebley. A scholar is included among the top collaborators of Mohamad Shebley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamad Shebley. Mohamad Shebley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ubrogepant: Mechanism of action, clinical and translational science 2024 ·Clinical and Translational Science ·Ramesh Boinpally, Mohamad Shebley, Joel M. Trugman	5
2	Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed‐Dose Combination Product: Phase 1 Results in Healthy Pre‐ and Postmenopausal Women 2024 ·Clinical Pharmacology in Drug Development ·(unknown), Patrick Marroum, Yi‐Lin Chiu, (unknown), Nael M. Mostafa, Mohamad Shebley	1
3	Atogepant: Mechanism of action, clinical and translational science 2024 ·Clinical and Translational Science ·Ramesh Boinpally, Mohamad Shebley, Joel M. Trugman	14
4	Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome 2023 ·F&S Reports ·Michael C. Snabes, Juki Ng, Hong Li, (unknown), Mohamad Shebley, William D. Schlaff	1
5	Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling 2023 ·The AAPS Journal ·Dwaipayan Mukherjee, (unknown), (unknown), (unknown), Mohamad Shebley, Patrick Marroum	5
6	Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids 2021 ·Clinical Pharmacokinetics ·(unknown), (unknown), Mohan Liu, Jacob F. Degner, Nael M. Mostafa, Peter Noertersheuser, Mohamad Shebley	4
7	Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life 2021 ·Journal of Women s Health ·Nelson B. Watts, Neil Binkley, Charlotte D. Owens, Ayman Al‐Hendy, Elizabeth E. Puscheck, Mohamad Shebley, William D. Schlaff, James A. Simon	16
8	Drug–Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy 2020 ·Clinical Pharmacokinetics ·Ahmed Nader, Nael M. Mostafa, (unknown), Mohamad Shebley	9
9	Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling 2019 ·Clinical Pharmacokinetics ·Manoj Chiney, Juki Ng, John P. Gibbs, Mohamad Shebley	21
10	Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis 2019 ·Clinical Pharmacokinetics ·Mohamad Shebley, Akshanth R. Polepally, Ahmed Nader, Juki Ng, (unknown), Cheri E. Klein, Peter Noertersheuser, Megan Gibbs, Nael M. Mostafa	45
11	Practical Assessment of Clinical Drug–Drug Interactions in Drug Development Using Physiologically Based Pharmacokinetics Modeling 2019 ·Clinical Pharmacology & Therapeutics ·Mohamad Shebley, Heidi J. Einolf	2
12	Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies 2018 ·Future Oncology ·Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Zhou, Jeremy A. Ross, Betty Prine, Mohamad Shebley, (unknown), Thalia A. Farazi, Su Young Kim, Maria Verdugo, (unknown), C. Michel Zwaan, Josef Vormoor	39
13	Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model 2018 ·Journal of Pharmacokinetics and Pharmacodynamics ·Dwaipayan Mukherjee, Jiuhong Zha, Rajeev Menon, Mohamad Shebley	21
14	Industry Perspective on Standardizing Food-Effect Studies for New Drug Development 2018 ·Clinical Pharmacokinetics ·Patrick Marroum, Silpa Nuthalapati, Apurvasena Parikh, Mohamad Shebley, David Hoffman, Jiuhong Zha, Amit Khatri, Walid M. Awni	2
15	Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir 2017 ·Drug Metabolism and Disposition ·Mohamad Shebley, Jinrong Liu, (unknown), Jens Sydor, Sonia M. de Morais, Volker Fischer, Marjoleen Nijsen, Daniel A.J. Bow	33
16	In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax 2017 ·Drug Metabolism and Pharmacokinetics ·Ryota Kikuchi, Mohamad Shebley, Daniel A.J. Bow, Robert A. Carr, Marjoleen Nijsen, Sonia M. de Morais	6
17	Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective 2016 ·Drug Metabolism and Disposition ·Odette A. Fahmi, Mohamad Shebley, Jairam Palamanda, Michael Sinz, Diane Ramsden, Heidi J. Einolf, (unknown), Hongwu Wang	38
18	Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data 2013 ·Clinical Pharmacology & Therapeutics ·Heidi J. Einolf, (unknown), Odette A. Fahmi, Christopher R. Gibson, R. Scott Obach, Mohamad Shebley, (unknown), Michael Sinz, Jashvant D. Unadkat, L Zhang, Ping Zhao	73
19	Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling 2009 ·Drug Metabolism and Disposition ·Mohamad Shebley, Ute M. Kent, David P. Ballou, Paul F. Hollenberg	10
20	Mutation of a Single Residue (K262R) in P450 2B6 Leads to Loss of Mechanism-Based Inactivation by Phencyclidine 2007 ·Drug Metabolism and Disposition ·Mohamad Shebley, Paul F. Hollenberg	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact